CA2558262A1 - Rnai-based therapeutics for allergic rhinitis and asthma - Google Patents

Info

Publication number

CA2558262A1

CA2558262A1 CA002558262A CA2558262A CA2558262A1 CA 2558262 A1 CA2558262 A1 CA 2558262A1 CA 002558262 A CA002558262 A CA 002558262A CA 2558262 A CA2558262 A CA 2558262A CA 2558262 A1 CA2558262 A1 CA 2558262A1

Authority

CA

Canada

Prior art keywords

sirna

composition

rnai agent

shrna

seq

Prior art date

2004-03-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 208000006673 asthma Diseases 0.000 title claims abstract description 47
• 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 34
• 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 34
• 201000009961 allergic asthma Diseases 0.000 title claims abstract description 26
• 108091030071 RNAI Proteins 0.000 title claims abstract 53
• 239000003814 drug Substances 0.000 title claims description 23
• 230000009368 gene silencing by RNA Effects 0.000 claims abstract description 390
• 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 357
• 239000003795 chemical substances by application Substances 0.000 claims abstract description 340
• 108091027967 Small hairpin RNA Proteins 0.000 claims abstract description 272
• 239000013598 vector Substances 0.000 claims abstract description 187
• 239000000203 mixture Substances 0.000 claims abstract description 177
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 139
• 238000000034 method Methods 0.000 claims abstract description 135
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 80
• 201000010099 disease Diseases 0.000 claims abstract description 74
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 73
• -1 ICOS Proteins 0.000 claims abstract description 65
• 208000001718 Immediate Hypersensitivity Diseases 0.000 claims abstract description 55
• 238000011282 treatment Methods 0.000 claims abstract description 48
• 230000001404 mediated effect Effects 0.000 claims abstract description 43
• 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract description 37
• 101150013553 CD40 gene Proteins 0.000 claims abstract description 36
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims abstract description 32
• 102000004473 OX40 Ligand Human genes 0.000 claims abstract description 32
• 108010042215 OX40 Ligand Proteins 0.000 claims abstract description 32
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims abstract description 32
• 102100035793 CD83 antigen Human genes 0.000 claims abstract description 28
• 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims abstract description 28
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims abstract description 28
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims abstract description 28
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims abstract description 28
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims abstract description 26
• 102000002627 4-1BB Ligand Human genes 0.000 claims abstract description 24
• 108010082808 4-1BB Ligand Proteins 0.000 claims abstract description 24
• 102100039360 Toll-like receptor 4 Human genes 0.000 claims abstract description 24
• 229940124447 delivery agent Drugs 0.000 claims abstract description 23
• 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims abstract description 19
• 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims abstract description 19
• 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims abstract description 19
• 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims abstract description 19
• 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims abstract description 19
• 102100024333 Toll-like receptor 2 Human genes 0.000 claims abstract description 19
• 102100024324 Toll-like receptor 3 Human genes 0.000 claims abstract description 19
• 102100039387 Toll-like receptor 6 Human genes 0.000 claims abstract description 19
• 102100039390 Toll-like receptor 7 Human genes 0.000 claims abstract description 19
• 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims abstract description 9
• 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims abstract description 9
• 102100027010 Toll-like receptor 1 Human genes 0.000 claims abstract description 9
• 102100033110 Toll-like receptor 8 Human genes 0.000 claims abstract description 9
• DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims abstract description 9
• 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims abstract 9
• 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims abstract 8
• 102100039357 Toll-like receptor 5 Human genes 0.000 claims abstract 8
• 102100033117 Toll-like receptor 9 Human genes 0.000 claims abstract 8
• 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 claims abstract 7
• 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims abstract 7
• 239000004055 small Interfering RNA Substances 0.000 claims description 482
• 210000004027 cell Anatomy 0.000 claims description 256
• 125000003729 nucleotide group Chemical group 0.000 claims description 156
• 239000002773 nucleotide Substances 0.000 claims description 152
• 230000000295 complement effect Effects 0.000 claims description 138
• 230000014509 gene expression Effects 0.000 claims description 138
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 117
• 150000007523 nucleic acids Chemical class 0.000 claims description 87
• 230000000692 anti-sense effect Effects 0.000 claims description 86
• 210000003630 histaminocyte Anatomy 0.000 claims description 80
• 229920000642 polymer Polymers 0.000 claims description 79
• 102000039446 nucleic acids Human genes 0.000 claims description 74
• 108020004707 nucleic acids Proteins 0.000 claims description 74
• 238000013518 transcription Methods 0.000 claims description 70
• 230000035897 transcription Effects 0.000 claims description 70
• 230000002401 inhibitory effect Effects 0.000 claims description 63
• 230000000694 effects Effects 0.000 claims description 55
• 229920006317 cationic polymer Polymers 0.000 claims description 53
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 53
• 238000004519 manufacturing process Methods 0.000 claims description 52
• 108091081021 Sense strand Proteins 0.000 claims description 51
• 230000005764 inhibitory process Effects 0.000 claims description 35
• 238000001415 gene therapy Methods 0.000 claims description 32
• 239000008194 pharmaceutical composition Substances 0.000 claims description 30
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 29
• 239000003184 complementary RNA Substances 0.000 claims description 29
• 208000024891 symptom Diseases 0.000 claims description 29
• 210000004241 Th2 cell Anatomy 0.000 claims description 26
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 25
• 239000004475 Arginine Substances 0.000 claims description 24
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 24
• 238000012986 modification Methods 0.000 claims description 24
• 241001465754 Metazoa Species 0.000 claims description 23
• 230000004048 modification Effects 0.000 claims description 23
• 230000028327 secretion Effects 0.000 claims description 23
• 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 22
• 108091007433 antigens Proteins 0.000 claims description 20
• 102000036639 antigens Human genes 0.000 claims description 20
• 230000036755 cellular response Effects 0.000 claims description 20
• 210000004072 lung Anatomy 0.000 claims description 20
• 239000000427 antigen Substances 0.000 claims description 19
• 108020004394 Complementary RNA Proteins 0.000 claims description 17
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 17
• 229920002873 Polyethylenimine Polymers 0.000 claims description 16
• 239000000443 aerosol Substances 0.000 claims description 14
• 230000006052 T cell proliferation Effects 0.000 claims description 12
• 230000001965 increasing effect Effects 0.000 claims description 12
• 210000002345 respiratory system Anatomy 0.000 claims description 12
• 102000002689 Toll-like receptor Human genes 0.000 claims description 11
• 108020000411 Toll-like receptor Proteins 0.000 claims description 11
• 230000006378 damage Effects 0.000 claims description 11
• 208000027418 Wounds and injury Diseases 0.000 claims description 10
• 230000001413 cellular effect Effects 0.000 claims description 10
• 208000014674 injury Diseases 0.000 claims description 10
• 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 10
• 108010011110 polyarginine Proteins 0.000 claims description 10
• 230000004083 survival effect Effects 0.000 claims description 10
• 238000011161 development Methods 0.000 claims description 9
• 230000035755 proliferation Effects 0.000 claims description 9
• 230000009261 transgenic effect Effects 0.000 claims description 9
• 206010040047 Sepsis Diseases 0.000 claims description 8
• 210000002966 serum Anatomy 0.000 claims description 8
• 230000035939 shock Effects 0.000 claims description 8
• 102000004127 Cytokines Human genes 0.000 claims description 7
• 108090000695 Cytokines Proteins 0.000 claims description 7
• 210000002443 helper t lymphocyte Anatomy 0.000 claims description 7
• 239000000843 powder Substances 0.000 claims description 7
• 239000004094 surface-active agent Substances 0.000 claims description 7
• 229920001661 Chitosan Polymers 0.000 claims description 6
• 238000010521 absorption reaction Methods 0.000 claims description 6
• 229940079593 drug Drugs 0.000 claims description 6
• 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
• 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 5
• 239000007922 nasal spray Substances 0.000 claims description 5
• 230000008506 pathogenesis Effects 0.000 claims description 5
• 230000009325 pulmonary function Effects 0.000 claims description 5
• 230000001177 retroviral effect Effects 0.000 claims description 5
• 125000002652 ribonucleotide group Chemical group 0.000 claims description 5
• 208000037883 airway inflammation Diseases 0.000 claims description 4
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 4
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
• 229940097496 nasal spray Drugs 0.000 claims description 4
• 238000007634 remodeling Methods 0.000 claims description 4
• 239000005547 deoxyribonucleotide Substances 0.000 claims description 3
• 125000002637 deoxyribonucleotide group Chemical group 0.000 claims description 3
• 230000009257 reactivity Effects 0.000 claims description 3
• 235000000346 sugar Nutrition 0.000 claims description 3
• 241000702421 Dependoparvovirus Species 0.000 claims description 2
• 102000014450 RNA Polymerase III Human genes 0.000 claims description 2
• 108010078067 RNA Polymerase III Proteins 0.000 claims description 2
• 108700009124 Transcription Initiation Site Proteins 0.000 claims description 2
• 238000010438 heat treatment Methods 0.000 claims description 2
• 208000037891 myocardial injury Diseases 0.000 claims description 2
• 230000003248 secreting effect Effects 0.000 claims description 2
• 241000701161 unidentified adenovirus Species 0.000 claims description 2
• 241001334141 Rugopharynx alpha Species 0.000 claims 3
• 108091028664 Ribonucleotide Proteins 0.000 claims 1
• 239000002336 ribonucleotide Substances 0.000 claims 1
• 230000000241 respiratory effect Effects 0.000 abstract description 4
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 336
• 108020004414 DNA Proteins 0.000 description 55
• 241000282414 Homo sapiens Species 0.000 description 50
• 210000004443 dendritic cell Anatomy 0.000 description 42
• 241000699670 Mus sp. Species 0.000 description 40
• 230000004044 response Effects 0.000 description 39
• 235000018102 proteins Nutrition 0.000 description 38
• 241000699666 Mus <mouse, genus> Species 0.000 description 37
• 239000013612 plasmid Substances 0.000 description 36
• 230000015572 biosynthetic process Effects 0.000 description 35
• 238000003786 synthesis reaction Methods 0.000 description 33
• 235000009697 arginine Nutrition 0.000 description 28
• 230000002829 reductive effect Effects 0.000 description 28
• 102000004196 processed proteins & peptides Human genes 0.000 description 27
• 238000001890 transfection Methods 0.000 description 27
• 238000012360 testing method Methods 0.000 description 26
• 230000001225 therapeutic effect Effects 0.000 description 24
• 150000001875 compounds Chemical class 0.000 description 23
• 239000013566 allergen Substances 0.000 description 20
• 241000700605 Viruses Species 0.000 description 19
• 210000002540 macrophage Anatomy 0.000 description 19
• 230000007423 decrease Effects 0.000 description 18
• 210000004962 mammalian cell Anatomy 0.000 description 18
• 238000001727 in vivo Methods 0.000 description 16
• 239000002243 precursor Substances 0.000 description 16
• 229920002477 rna polymer Polymers 0.000 description 16
• 108020005544 Antisense RNA Proteins 0.000 description 15
• 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 15
• 238000013459 approach Methods 0.000 description 15
• 238000013461 design Methods 0.000 description 15
• 230000002265 prevention Effects 0.000 description 15
• 102000005962 receptors Human genes 0.000 description 15
• 108020003175 receptors Proteins 0.000 description 15
• 206010020751 Hypersensitivity Diseases 0.000 description 14
• 229920001184 polypeptide Polymers 0.000 description 14
• 230000001105 regulatory effect Effects 0.000 description 14
• 238000003556 assay Methods 0.000 description 13
• 230000003247 decreasing effect Effects 0.000 description 13
• 238000011156 evaluation Methods 0.000 description 13
• 238000009396 hybridization Methods 0.000 description 13
• 230000003834 intracellular effect Effects 0.000 description 13
• 239000002245 particle Substances 0.000 description 13
• 238000010171 animal model Methods 0.000 description 12
• 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 11
• 208000026935 allergic disease Diseases 0.000 description 11
• 210000003651 basophil Anatomy 0.000 description 11
• 230000002452 interceptive effect Effects 0.000 description 11
• 239000003446 ligand Substances 0.000 description 11
• 238000012545 processing Methods 0.000 description 11
• 210000001519 tissue Anatomy 0.000 description 11
• 238000013519 translation Methods 0.000 description 11
• YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 10
• 230000030279 gene silencing Effects 0.000 description 10
• 241000282412 Homo Species 0.000 description 9
• 108700011259 MicroRNAs Proteins 0.000 description 9
• 108091028043 Nucleic acid sequence Proteins 0.000 description 9
• 108091034117 Oligonucleotide Proteins 0.000 description 9
• 239000002585 base Substances 0.000 description 9
• 230000015556 catabolic process Effects 0.000 description 9
• 239000002299 complementary DNA Substances 0.000 description 9
• 238000006731 degradation reaction Methods 0.000 description 9
• 230000007246 mechanism Effects 0.000 description 9
• 230000037361 pathway Effects 0.000 description 9
• 239000000243 solution Substances 0.000 description 9
• 230000003612 virological effect Effects 0.000 description 9
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
• 108010039918 Polylysine Proteins 0.000 description 8
• 230000004913 activation Effects 0.000 description 8
• 231100000135 cytotoxicity Toxicity 0.000 description 8
• 230000003013 cytotoxicity Effects 0.000 description 8
• 230000018109 developmental process Effects 0.000 description 8
• 230000006870 function Effects 0.000 description 8
• 238000001476 gene delivery Methods 0.000 description 8
• 238000000338 in vitro Methods 0.000 description 8
• 108020004999 messenger RNA Proteins 0.000 description 8
• 229920000656 polylysine Polymers 0.000 description 8
• 238000012552 review Methods 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• 108020005345 3' Untranslated Regions Proteins 0.000 description 7
• 241000713666 Lentivirus Species 0.000 description 7
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
• 230000000172 allergic effect Effects 0.000 description 7
• 208000010668 atopic eczema Diseases 0.000 description 7
• 125000002091 cationic group Chemical group 0.000 description 7
• WNKZOJNKBOBRAY-UHFFFAOYSA-N cdba Chemical compound O=CC1=CC=CC=C1.O1C(C(C2O)O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC(C(O)C2O)C(COC)OC2OC(C(C2O)O)C(COC)OC2OC2C(O)C(O)C1OC2COC WNKZOJNKBOBRAY-UHFFFAOYSA-N 0.000 description 7
• 238000004113 cell culture Methods 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 238000001990 intravenous administration Methods 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 230000002685 pulmonary effect Effects 0.000 description 7
• 241000894007 species Species 0.000 description 7
• 238000012546 transfer Methods 0.000 description 7
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• 241000283984 Rodentia Species 0.000 description 6
• 230000007815 allergy Effects 0.000 description 6
• 150000001484 arginines Chemical class 0.000 description 6
• 208000035475 disorder Diseases 0.000 description 6
• 210000000981 epithelium Anatomy 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 239000002679 microRNA Substances 0.000 description 6
• 239000000178 monomer Substances 0.000 description 6
• 210000003097 mucus Anatomy 0.000 description 6
• 229920000747 poly(lactic acid) Polymers 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 239000013603 viral vector Substances 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 102000004190 Enzymes Human genes 0.000 description 5
• 108090000790 Enzymes Proteins 0.000 description 5
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
• 102100038006 High affinity immunoglobulin epsilon receptor subunit alpha Human genes 0.000 description 5
• 108050001540 High affinity immunoglobulin epsilon receptor subunit beta Proteins 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
• 210000000612 antigen-presenting cell Anatomy 0.000 description 5
• 229940114079 arachidonic acid Drugs 0.000 description 5
• 235000021342 arachidonic acid Nutrition 0.000 description 5
• 238000003491 array Methods 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 230000004071 biological effect Effects 0.000 description 5
• 230000037396 body weight Effects 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 210000000170 cell membrane Anatomy 0.000 description 5
• 229920001577 copolymer Polymers 0.000 description 5
• 210000002919 epithelial cell Anatomy 0.000 description 5
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
• 230000006698 induction Effects 0.000 description 5
• 230000001939 inductive effect Effects 0.000 description 5
• 239000002502 liposome Substances 0.000 description 5
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 241000712461 unidentified influenza virus Species 0.000 description 5
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• 238000009825 accumulation Methods 0.000 description 4
• 150000001412 amines Chemical class 0.000 description 4
• 230000004700 cellular uptake Effects 0.000 description 4
• 230000001684 chronic effect Effects 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 125000004386 diacrylate group Chemical group 0.000 description 4
• 239000006185 dispersion Substances 0.000 description 4
• 238000004520 electroporation Methods 0.000 description 4
• 230000012202 endocytosis Effects 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 238000002474 experimental method Methods 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 238000012226 gene silencing method Methods 0.000 description 4
• 229960001340 histamine Drugs 0.000 description 4
• 230000009610 hypersensitivity Effects 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 239000003112 inhibitor Substances 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 210000004698 lymphocyte Anatomy 0.000 description 4
• 210000000440 neutrophil Anatomy 0.000 description 4
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 4
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 4
• 238000011160 research Methods 0.000 description 4
• 238000010839 reverse transcription Methods 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 229940124597 therapeutic agent Drugs 0.000 description 4
• 229930024421 Adenine Natural products 0.000 description 3
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 108010078791 Carrier Proteins Proteins 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• 241000725303 Human immunodeficiency virus Species 0.000 description 3
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 241001494479 Pecora Species 0.000 description 3
• 101710149951 Protein Tat Proteins 0.000 description 3
• 102000003661 Ribonuclease III Human genes 0.000 description 3
• 108010057163 Ribonuclease III Proteins 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 230000006044 T cell activation Effects 0.000 description 3
• 108091023040 Transcription factor Proteins 0.000 description 3
• 102000040945 Transcription factor Human genes 0.000 description 3
• 108700019146 Transgenes Proteins 0.000 description 3
• 229960000643 adenine Drugs 0.000 description 3
• 230000005875 antibody response Effects 0.000 description 3
• 230000027455 binding Effects 0.000 description 3
• 150000001720 carbohydrates Chemical class 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 238000006243 chemical reaction Methods 0.000 description 3
• 208000037976 chronic inflammation Diseases 0.000 description 3
• 230000006020 chronic inflammation Effects 0.000 description 3
• 239000003246 corticosteroid Substances 0.000 description 3
• 229960001334 corticosteroids Drugs 0.000 description 3
• 230000002950 deficient Effects 0.000 description 3
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 210000003979 eosinophil Anatomy 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 206010020718 hyperplasia Diseases 0.000 description 3
• 238000003018 immunoassay Methods 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 230000010354 integration Effects 0.000 description 3
• 238000010253 intravenous injection Methods 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 3
• 229960002329 methacholine Drugs 0.000 description 3
• 239000011859 microparticle Substances 0.000 description 3
• 230000005012 migration Effects 0.000 description 3
• 238000013508 migration Methods 0.000 description 3
• 238000010172 mouse model Methods 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 235000021317 phosphate Nutrition 0.000 description 3
• 239000002953 phosphate buffered saline Substances 0.000 description 3
• 230000036515 potency Effects 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 210000000130 stem cell Anatomy 0.000 description 3
• 230000000638 stimulation Effects 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 230000032258 transport Effects 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
• 108700031308 Antennapedia Homeodomain Proteins 0.000 description 2
• 108091032955 Bacterial small RNA Proteins 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
• 102100023387 Endoribonuclease Dicer Human genes 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 2
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
• 241000287828 Gallus gallus Species 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
• 206010020880 Hypertrophy Diseases 0.000 description 2
• 102000009438 IgE Receptors Human genes 0.000 description 2
• 108010073816 IgE Receptors Proteins 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 108090000176 Interleukin-13 Proteins 0.000 description 2
• 108090000978 Interleukin-4 Proteins 0.000 description 2
• 108010002616 Interleukin-5 Proteins 0.000 description 2
• 206010054949 Metaplasia Diseases 0.000 description 2
• 101710163270 Nuclease Proteins 0.000 description 2
• 108010058846 Ovalbumin Proteins 0.000 description 2
• 108010033276 Peptide Fragments Proteins 0.000 description 2
• 102000007079 Peptide Fragments Human genes 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 2
• 206010070834 Sensitisation Diseases 0.000 description 2
• 241000282898 Sus scrofa Species 0.000 description 2
• 230000020385 T cell costimulation Effects 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
• 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
• DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 239000008351 acetate buffer Substances 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 208000038016 acute inflammation Diseases 0.000 description 2
• 230000006022 acute inflammation Effects 0.000 description 2
• 239000000048 adrenergic agonist Substances 0.000 description 2
• 208000037884 allergic airway inflammation Diseases 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000000844 anti-bacterial effect Effects 0.000 description 2
• 229940125715 antihistaminic agent Drugs 0.000 description 2
• 239000000739 antihistaminic agent Substances 0.000 description 2
• 229960005070 ascorbic acid Drugs 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 208000010216 atopic IgE responsiveness Diseases 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 239000000227 bioadhesive Substances 0.000 description 2
• 239000012620 biological material Substances 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 229940124630 bronchodilator Drugs 0.000 description 2
• 239000000168 bronchodilator agent Substances 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000003915 cell function Effects 0.000 description 2
• 238000012512 characterization method Methods 0.000 description 2
• 235000013330 chicken meat Nutrition 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 210000004748 cultured cell Anatomy 0.000 description 2
• 210000000805 cytoplasm Anatomy 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000010586 diagram Methods 0.000 description 2
• 101150083707 dicer1 gene Proteins 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 2
• 230000003828 downregulation Effects 0.000 description 2
• 210000001163 endosome Anatomy 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• 230000029142 excretion Effects 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 230000004761 fibrosis Effects 0.000 description 2
• 230000005714 functional activity Effects 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 230000002458 infectious effect Effects 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 229960000367 inositol Drugs 0.000 description 2
• 230000008611 intercellular interaction Effects 0.000 description 2
• 230000010468 interferon response Effects 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 238000001638 lipofection Methods 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 231100000053 low toxicity Toxicity 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 239000006166 lysate Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 230000015689 metaplastic ossification Effects 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 108091070501 miRNA Proteins 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 230000002025 microglial effect Effects 0.000 description 2
• 239000002105 nanoparticle Substances 0.000 description 2
• 239000006199 nebulizer Substances 0.000 description 2
• 239000013642 negative control Substances 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 229940092253 ovalbumin Drugs 0.000 description 2
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
• 229960001412 pentobarbital Drugs 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 239000000825 pharmaceutical preparation Substances 0.000 description 2
• 230000000144 pharmacologic effect Effects 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 230000001124 posttranscriptional effect Effects 0.000 description 2
• 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 150000003141 primary amines Chemical group 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 150000003180 prostaglandins Chemical class 0.000 description 2
• 150000003230 pyrimidines Chemical class 0.000 description 2
• 239000000523 sample Substances 0.000 description 2
• 230000008313 sensitization Effects 0.000 description 2
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
• 230000011664 signaling Effects 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 230000001629 suppression Effects 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• 230000002123 temporal effect Effects 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 241001529453 unidentified herpesvirus Species 0.000 description 2
• 241001430294 unidentified retrovirus Species 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 229920003169 water-soluble polymer Polymers 0.000 description 2
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
• 229930182837 (R)-adrenaline Natural products 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• FXYZDFSNBBOHTA-UHFFFAOYSA-N 2-[amino(morpholin-4-ium-4-ylidene)methyl]guanidine;chloride Chemical compound Cl.NC(N)=NC(=N)N1CCOCC1 FXYZDFSNBBOHTA-UHFFFAOYSA-N 0.000 description 1
• 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
• RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
• 208000000884 Airway Obstruction Diseases 0.000 description 1
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
• 235000017060 Arachis glabrata Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000018262 Arachis monticola Nutrition 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• 108010029697 CD40 Ligand Proteins 0.000 description 1
• 102100032937 CD40 ligand Human genes 0.000 description 1
• 241000244203 Caenorhabditis elegans Species 0.000 description 1
• 101100109216 Caenorhabditis elegans apy-1 gene Proteins 0.000 description 1
• 101100063069 Caenorhabditis elegans deg-1 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
• 241001432959 Chernes Species 0.000 description 1
• PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
• 241000501458 Cultus Species 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• 206010011763 Cystic fibrosis lung Diseases 0.000 description 1
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• 108091029865 Exogenous DNA Proteins 0.000 description 1
• 108700024394 Exon Proteins 0.000 description 1
• 108060002716 Exonuclease Proteins 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 208000004262 Food Hypersensitivity Diseases 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
• 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
• 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
• 108700005087 Homeobox Genes Proteins 0.000 description 1
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
• 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 description 1
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
• 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 1
• 101150101999 IL6 gene Proteins 0.000 description 1
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
• 208000006877 Insect Bites and Stings Diseases 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 108090000174 Interleukin-10 Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 108091092195 Intron Proteins 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 241000272168 Laridae Species 0.000 description 1
• 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
• 239000012097 Lipofectamine 2000 Substances 0.000 description 1
• 231100000002 MTT assay Toxicity 0.000 description 1
• 238000000134 MTT assay Methods 0.000 description 1
• 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
• 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• 108060004795 Methyltransferase Proteins 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 108700026244 Open Reading Frames Proteins 0.000 description 1
• 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 108010043958 Peptoids Proteins 0.000 description 1
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 102000016611 Proteoglycans Human genes 0.000 description 1
• 108010067787 Proteoglycans Proteins 0.000 description 1
• 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
• 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
• 102000009572 RNA Polymerase II Human genes 0.000 description 1
• 108010009460 RNA Polymerase II Proteins 0.000 description 1
• 230000007022 RNA scission Effects 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 208000036071 Rhinorrhea Diseases 0.000 description 1
• 206010039101 Rhinorrhoea Diseases 0.000 description 1
• 102000006382 Ribonucleases Human genes 0.000 description 1
• 108010083644 Ribonucleases Proteins 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
• 108700012920 TNF Proteins 0.000 description 1
• 101710192266 Tegument protein VP22 Proteins 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 108091036066 Three prime untranslated region Proteins 0.000 description 1
• 102000002262 Thromboplastin Human genes 0.000 description 1
• 108010000499 Thromboplastin Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 206010045240 Type I hypersensitivity Diseases 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
• 108700005077 Viral Genes Proteins 0.000 description 1
• 101150003160 X gene Proteins 0.000 description 1
• 108091027569 Z-DNA Proteins 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
• CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000011543 agarose gel Substances 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000036428 airway hyperreactivity Effects 0.000 description 1
• 230000010085 airway hyperresponsiveness Effects 0.000 description 1
• 230000008369 airway response Effects 0.000 description 1
• NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 230000009285 allergic inflammation Effects 0.000 description 1
• 125000005336 allyloxy group Chemical group 0.000 description 1
• 229940037003 alum Drugs 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 239000002269 analeptic agent Substances 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• 210000003484 anatomy Anatomy 0.000 description 1
• 125000000129 anionic group Chemical group 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 230000006472 autoimmune response Effects 0.000 description 1
• 230000003385 bacteriostatic effect Effects 0.000 description 1
• 210000004082 barrier epithelial cell Anatomy 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 238000005284 basis set Methods 0.000 description 1
• 235000019445 benzyl alcohol Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
• 239000003833 bile salt Substances 0.000 description 1
• 229940093761 bile salts Drugs 0.000 description 1
• 230000008238 biochemical pathway Effects 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 230000007885 bronchoconstriction Effects 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 239000003710 calcium ionophore Substances 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 210000004413 cardiac myocyte Anatomy 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000011712 cell development Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 210000004671 cell-free system Anatomy 0.000 description 1
• 230000008614 cellular interaction Effects 0.000 description 1
• 229960001803 cetirizine Drugs 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000003837 chick embryo Anatomy 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 239000013611 chromosomal DNA Substances 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 230000015271 coagulation Effects 0.000 description 1
• 238000005345 coagulation Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 238000004891 communication Methods 0.000 description 1
• 230000006854 communication Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 230000009091 contractile dysfunction Effects 0.000 description 1
• 238000013270 controlled release Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 229960000265 cromoglicic acid Drugs 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 210000000172 cytosol Anatomy 0.000 description 1
• 239000000850 decongestant Substances 0.000 description 1
• 229940124581 decongestants Drugs 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 230000029087 digestion Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 230000009881 electrostatic interaction Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 108010027836 endotoxin receptor Proteins 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229960005139 epinephrine Drugs 0.000 description 1
• 230000001667 episodic effect Effects 0.000 description 1
• 230000004890 epithelial barrier function Effects 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 102000013165 exonuclease Human genes 0.000 description 1
• 208000024711 extrinsic asthma Diseases 0.000 description 1
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
• 229960003592 fexofenadine Drugs 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 238000000684 flow cytometry Methods 0.000 description 1
• 229960002714 fluticasone Drugs 0.000 description 1
• MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
• 239000013568 food allergen Substances 0.000 description 1
• 235000020932 food allergy Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• ZXQYGBMAQZUVMI-GCMPRSNUSA-N gamma-cyhalothrin Chemical compound CC1(C)[C@@H](\C=C(/Cl)C(F)(F)F)[C@H]1C(=O)O[C@H](C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 ZXQYGBMAQZUVMI-GCMPRSNUSA-N 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
• 229940029575 guanosine Drugs 0.000 description 1
• 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
• 125000001475 halogen functional group Chemical group 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 230000002390 hyperplastic effect Effects 0.000 description 1
• 230000004047 hyperresponsiveness Effects 0.000 description 1
• 238000013095 identification testing Methods 0.000 description 1
• 125000000879 imine group Chemical group 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000003701 inert diluent Substances 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 206010022000 influenza Diseases 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 1
• 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 1
• 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
• 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 description 1
• 108040006861 interleukin-7 receptor activity proteins Proteins 0.000 description 1
• 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
• 230000031146 intracellular signal transduction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 229940039009 isoproterenol Drugs 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 231100000636 lethal dose Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 239000008263 liquid aerosol Substances 0.000 description 1
• 229960003088 loratadine Drugs 0.000 description 1
• JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 238000004890 malting Methods 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 238000002483 medication Methods 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000004779 membrane envelope Anatomy 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 238000002493 microarray Methods 0.000 description 1
• 238000010208 microarray analysis Methods 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 229940051866 mouthwash Drugs 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• 210000002850 nasal mucosa Anatomy 0.000 description 1
• 239000006218 nasal suppository Substances 0.000 description 1
• 229960004398 nedocromil Drugs 0.000 description 1
• RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000014511 neuron projection development Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 231100000255 pathogenic effect Toxicity 0.000 description 1
• 230000035778 pathophysiological process Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 102000007863 pattern recognition receptors Human genes 0.000 description 1
• 108010089193 pattern recognition receptors Proteins 0.000 description 1
• 235000020232 peanut Nutrition 0.000 description 1
• MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
• 108010043655 penetratin Proteins 0.000 description 1
• 230000035515 penetration Effects 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
• 229940065514 poly(lactide) Drugs 0.000 description 1
• 239000008389 polyethoxylated castor oil Substances 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 238000011809 primate model Methods 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 229940127293 prostanoid Drugs 0.000 description 1
• 150000003814 prostanoids Chemical class 0.000 description 1
• 238000012383 pulmonary drug delivery Methods 0.000 description 1
• 238000009613 pulmonary function test Methods 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 229940044551 receptor antagonist Drugs 0.000 description 1
• 239000002464 receptor antagonist Substances 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 230000003362 replicative effect Effects 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229960002052 salbutamol Drugs 0.000 description 1
• 229960004017 salmeterol Drugs 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 238000001338 self-assembly Methods 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 125000005629 sialic acid group Chemical group 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 230000016160 smooth muscle contraction Effects 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 231100001274 therapeutic index Toxicity 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 230000032895 transmembrane transport Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 230000009959 type I hypersensitivity Effects 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
• 229940045145 uridine Drugs 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 230000024883 vasodilation Effects 0.000 description 1
• 238000009423 ventilation Methods 0.000 description 1
• 230000017613 viral reproduction Effects 0.000 description 1
• 210000000605 viral structure Anatomy 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1